Study 13 of 15Liraglutide literatureThe lancet. Diabetes & endocrinologyTop journal2026
Soaring GLP-1 receptor agonist use.
Not reported in abstract.
Where it sits
this study against the rest of the liraglutide corpus4
Preclinical · this one
7
Observational
0
Open-label
2
Randomised
2
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Liraglutide corpus
DComparative Exposure-Adjusted Adverse Reaction Reporting Rates for GLP-1-Based Therapies: An Analysis of UK MHRA Yellow Card Data and NHS Prescribing Data for Englandbiorxiv-preprint · 2026 · Liraglutide 1,326.64 (1,268.16–1,387.82) per million items.reviewCMulberry leaf flavonoids alleviate type 2 diabetes by remodeling the gut microbiota-bile acid axis and activating FXR signaling.Journal of ethnopharmacology · 2026 · Fasting blood glucose reduced significantly, p<0.05.AnimalDA systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Updatebiorxiv-preprint · 2026 · Not reported in abstract.reviewBComparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes Mellitusbiorxiv-preprint · 2026 · meta-analytic HR 1.05 for 3-point MACE (95% CI 0.79-1.39)HumanBCLINICAL CHARACTERISTICS OF USERS OF WEIGHT LOSS DRUGS: POPULATION-BASED CASE-CONTROL STUDYbiorxiv-preprint · 2026 · 4,603 liraglutide users identified during 2023-2024.HumanBRisk of Allodynia with GLP-1 Agonistsbiorxiv-preprint · 2026 · aHR 2.15 (95% CI 1.57–2.96)Human